Health affairs scholar · 2026
"Am I a candidate for magic mushrooms?" A mystery shopper study of Oregon psilocybin service centers.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Adams Danielle R, Hartman Morgan, Gong Lisa, Shankar Suraj, Ling Ruth, Steinle Jacob T, Siegel Joshua S, Nicol Ginger E, Grucza Richard A, Borodovsky Jacob T, Cabassa Leopoldo J, Xu Kevin Y
Аннотация
INTRODUCTION: Oregon is the first US state to permit supervised psilocybin services through a nonmedical, wellness-based model. We examined what prospective clients with psychiatric histories encounter when contacting service centers, including how staff communicate about safety, eligibility, and cost.
METHODS: We conducted a mystery shopper study of 26 licensed service centers in Oregon (7/2025-9/2025), 4 of which closed before calls began, leaving 22 in the sample. We reviewed websites and conducted 2 waves of scripted phone calls portraying adults with depression. Website and call data were combined at the center level, counting an item as disclosed if it appeared online or during a call. Themes from call field notes were contextualized through structured debriefing interviews with service center staff.
RESULTS: Callers reached 15/22 centers, none of which permitted unsupervised consumption or immediate dosing without psychiatric assessment. Staff asked detailed questions about psychiatric comorbidities, addressing information gaps from websites, and none recommended discontinuing antidepressants. The median cost was $1900. Debriefing interviews described financial strain for service centers, with viability constrained by licensing fees and potential misalignment with cannabis-derived business models.
CONCLUSION: Oregon's regulated model appears clinically cautious, while facing high costs for clients, facilitators, and service centers that limit scalability.
METHODS: We conducted a mystery shopper study of 26 licensed service centers in Oregon (7/2025-9/2025), 4 of which closed before calls began, leaving 22 in the sample. We reviewed websites and conducted 2 waves of scripted phone calls portraying adults with depression. Website and call data were combined at the center level, counting an item as disclosed if it appeared online or during a call. Themes from call field notes were contextualized through structured debriefing interviews with service center staff.
RESULTS: Callers reached 15/22 centers, none of which permitted unsupervised consumption or immediate dosing without psychiatric assessment. Staff asked detailed questions about psychiatric comorbidities, addressing information gaps from websites, and none recommended discontinuing antidepressants. The median cost was $1900. Debriefing interviews described financial strain for service centers, with viability constrained by licensing fees and potential misalignment with cannabis-derived business models.
CONCLUSION: Oregon's regulated model appears clinically cautious, while facing high costs for clients, facilitators, and service centers that limit scalability.